Loading provider…
Loading provider…
Ophthalmology Physician in Newport Beach, CA
NPI: 1255435822Primary Practice Location
David L. Wirta M.D. Inc.
520 Superior Ave, Newport Beach, CA
Primary Employer
David L. Wirta M.D. Inc.
drwirta.com
HQ Phone
Get MD David's Phone NumberMobile
Get MD David's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
OR State Medical License
1997
CA State Medical License
1995 - 2026

American Board of Ophthalmology
Ophthalmology
UCLA David Geffen School of Medicine/UCLA Medical Center/UCLA Stein and Doheny Eye Institutes
Residency • Ophthalmology
1994 - 1997
Los Angeles County-Harbor-UCLA Medical Center
Internship • Transitional Year
1993 - 1994
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 1993
Repository Corticotropin Injection (Acthar® Gel) for Refractory Severe Noninfectious Keratitis: Efficacy and Safety from a Phase 4, Multicenter, Open-Label Study.
Authors: David Wirta, Eugene Mclaurin, George Ousler, Jingyu Liu, R Kacmaz, Joseph Grieco
Publication Date: 2021-07-23
Reversal of Pharmacologically Induced Mydriasis with Phentolamine Ophthalmic Solution.
Authors: Pepose, Jay S, Wirta, David, Evans, David, Withers, Barbara, Rahmani, Kavon, Lazar, Audrey, Coleman, Drey, Patel, Ronil, Jaber, Reda, Sooch, Mina, Brigell, Mitchell, Charizanis, Konstantinos
Journal: Ophthalmology
Publication Date: 2024-09-16
Lead Sponsor: Aerie Pharmaceuticals
Intervention / Treatment: DRUG: AR-15512 Ophthalmic Solution, DRUG: AR-15512 Ophthalmic Solution Vehicle
Lead Sponsor: Surface Ophthalmics, Inc.
Intervention / Treatment: DRUG: Lifitegrast 5% Ophthalmic Solution, DRUG: SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), DRUG: Mycophenolic Acid 0.1%, DRUG: Mycophenolic Acid 0.3%, DRUG: Betamethasone Sodium Phosphate 0.01%, DRUG: Placebo Comparator: Vehicle, DRUG: Cyclosporine 0.05% Ophthalmic Emulsion
Lead Sponsor: Tarsus Pharmaceuticals, Inc.
Intervention / Treatment: DRUG: TP-03 Vehicle, DRUG: TP-03, 0.25%